Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

How is artificial intelligence shaking up the pharma marketing space? Ted Sweetser: The first top level one that everyone is ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

Ted Sweetser discusses how the technology is providing greater insight into how marketing materials are being viewed.